(AP) — Le Bonheur Children's Hospital will begin testing what researchers consider to be a promising new medicine on babies infected with a respiratory virus that's the leading cause of the hospitalization of infants nationwide. Le Bonheur medical director Dr. John DeVincenzo told The Commercial Appeal (http://bit.ly/1I8dcGT) that the antiviral drug known as ALS-008176 could redefine how the respiratory syncytial virus, or RSV, is handled.